Our weight loss offering is cash-pay only, so youll need to pay out of pocket
Its easy to use and is designed to fit into your everyday life
Two emerging pharmacological classes may challenge its risk-reward calculus: Oral GLP-1 agonists (e.g., oral semaglutide, danuglipron): These offer dosing convenience and eliminate injection site reactions, but bioavailability remains problematic (oral semaglutide achieves only 0.41% absorption, requiring daily dosing and strict administration protocols)
Retatrutides Phase 2 results landed on the cover of the New England Journal of Medicine in 2023, before Phase 3 even finished
Formulation studies explore stability, reconstitution parameters, and storage conditions suitable for laboratory workflows
If you regain the weight you lost, your face may start looking fuller again, too